Jvion, an AI-enabled prescriptive analytics company that aims to prevent harms, has joined ranks with integrated care network Novant Health to become the first member of the Novant Health Institute of Innovation & Artificial Intelligence.
The two organizations are specifically focused on reducing admissions for congestive heart failure (CHF) patients, which can be as high as 35% in the first year and can double with hospitalizations after. More broadly, the institute focuses on identifying advanced technologies and accelerating solutions for personalized care and to leverage actionable data and insight for predictive prevention, diagnosis and treatment of Novant patients.
Jvion will provide AI technology and the partnership will integrate clinical and socioeconomic data to identify relevant patient interventions. Specifically, Novant Health, based in North Carolina, will utilize the Jvion Machine, which pinpoints patients who can be impacted by a changeable risk trajectory and provides patient-specific recommendations for better outcomes.
“We are excited to continue implementing AI-based treatment modalities for our patients and bringing these transformational technologies to Novant Health and the communities we serve,” Eric Eskioglu, MD, Novant Health executive vice president and chief medical officer, said in a statement. “Partnering with innovators in analytics like Jvion allows us to anticipate risk factors and effectively intervene through personalized treatment plans for our patients, saving time and money.
Already, Jvion has reduced CHF readmissions 13% on average, preventing 130 readmissions out of 1,000 discharges. The savings are estimated to be about $1 million. By identifying patients at risk of harmful events, the level of higher risk and clinical and socioeconomic determinants causing the risk, the Jvion Machine recommends personalized interventions to change a patient’s trajectory. The technology will be deployed through Microsoft Azure as a “cloud instance,” according to the announcement.
“AI-enabled prescriptive analytics represent a new, innovative approach to using clinical and socioeconomic data to pinpoint the most impactful interventions for individuals suffering from diseases, such as CHF, that can be managed or prevented,” Shantanu Nigam, Jvion CEO, said in a statement. “We are excited to partner with Novant Health, a leader committed to leveraging new technologies to save lives, improve quality of care and impact key quality measures.”